Global and China Vitamin C Industry 2013 Deep Research Report

This is a professional and depth research report on Global and China Vitamin C (Food Grade Feed Grade Pharmaceutical Grade) Industry. Firstly the report describes the background knowledge of Vitamin C, including Vitamin C ((Food Grade Feed Grade Pharmaceutical Grade) Concepts Classification production process technical parameters; then statistics Global and China 14 Manufacturers Vitamin C product 2010-2016 Capacity production cost price production value Gross margins and other relevant data, statistics these enterprises Vitamin C products, customers, raw materials, company background information, then summary statistics and analysis the relevant data of these enterprises. and get Global and China Vitamin C 2010-2016 production market share, different Type Vitamin C production market share, Global and China Vitamin C demand supply and shortage, Global and China Vitamin C 2010-2016 production price cost Gross production value gross margins, etc. At the same time, the report analyzed and discussed supply and demand changes in Vitamin C market and business development strategies, conduct a comprehensive analysis on Global and China Vitamin C industry trends. Finally, the report also introduced 10KT/year Vitamin C project Feasibility analysis and related research conclusions. In a word, It was a depth research report on Global and China Vitamin C industry. And thanks to the support and assistance from Vitamin C industry chain related experts and enterprises during Research Team survey and interviews.

Buy a copy of this report @ http://www.reportsnreports.com/reports/214984-2013-deep-research-report-on-global-and-china-vitamin-c-industry.html.

Report Details:
Published: January 2013
No. of Pages: 111
Price:Single User License:US$2000 Corporate User License:US$4000



Table of Contents

Chapter One Food Grade Vitamin C Industry Overview 1
1.1 Food Grade Vitamin C Definition 1
1.2 Food Grade Vitamin C Product Specifications 1
1.3 Food Grade Vitamin C Price Analysis 2
1.4 Food Grade Vitamin C Manufacturing Process 2
1.5 Food Grade Vitamin C Cost Structure 3
1.6 Food Grade Vitamin C Industry Overview 4

Chapter Two Pharmaceutical Grade Vitamin C Industry Overview 4
2.1 Pharmaceutical Grade Vitamin C Definition 5
2.2 Pharmaceutical Grade Vitamin C Product Specifications 5
2.3 Pharmaceutical Grade Vitamin C Price Analysis 6
2.4 Pharmaceutical Grade Vitamin C Manufacturing Process 6
2.5 Pharmaceutical Grade Vitamin C Cost Structure 7
2.6 Pharmaceutical Grade Vitamin C Industry Overview 8

Chapter Three Feed Grade Vitamin C Industry Overview 8
3.1 Feed Grade Vitamin C Definition 9
3.2 Feed Grade Vitamin C Product Specifications 9
3.3 Feed Grade Vitamin C Price Analysis 10
3.4 Feed Grade Vitamin C Manufacturing Process 10
3.5 Feed Grade Vitamin C Cost Structure 11
3.6 Feed Grade Vitamin C Industry Overview 12

Chapter Four Vitamin C Industry Chain Analysis 12
4.1 Vitamin C Market Analysis 12
4.2 Vitamin C Industry Chain Analysis 13
Chapter Five Vitamin C Production Supply Sales Demand Market Status and Forecast 15
5.1 Global Vitamin C Capacity Production Overview 15
5.2 China Vitamin C Capacity Production Overview 29
5.3 Netherland China United States etc Regions Vitamin C Production and Market Share 43
5.4 Food Grade Pharmaceutical Grade Feed Grade Vitamin C Production and Market Share 44
5.5 Global and China Key Manufacturers Vitamin C Capacity Utilization Rate 47
5.6 China Vitamin C Capacity Production and Its Global Proportion 49
5.7 Global and China Vitamin C Demand Overview 51
5.8 Global and China Vitamin C Supply Demand Shortage 53
5.9 Global and China Vitamin C Cost Price Production Value Gross Margin 55
5.10 China Vitamin C Import Export Consumption 58

Chapter Six Vitamin C Key Manufacturers 60
6.1 DSM (Netherland) 60
6.2 CSPC Pharmaceutical Group 66
6.3 Northeast Pharmaceutical Group 73
6.4 Northchina Pharmaceutical Group 79
6.5 Aland Nutraceutical Group 86
6.6 Shandong Luwei Pharmaceutical 92

Chapter Seven Vitamin C New Project Investment Feasibility Analysis 98
7.1 Vitamin C New Project SWOT Analysis 98
7.2 10KT/Year Vitamin C New Project Investment Feasibility Analysis 99

Chapter Eight Vitamin C Industry Research Conclusions 99

Contact sales@reportsandreports.com for further information on this report.

Future Horizons in the Global Enteric Disease Market

This report presents detailed analysis of the Enteric Disease market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on epidemiology and etiology are presented for Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, Vibrio and Yersinia. The report provides test volume and sales forecasts by country and market segment, including: - Hospitals - Commercial/Private Labs - Physician Offices - Public Health LabsIn addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of enteric disease diagnostic products, by test and country. Also, the report: - Examines market applications of Molecular Diagnostics,Monoclonal Antibodies, Immunoassays, IT and other emerging technologies; - Reviews features and operating characteristics of major analyzers used for enteric disease testing; - Profiles key suppliers and potential market entrants developing innovativetechnologies and products; and - Analyzes emerging opportunities, alternative market penetration strategies, market entry barriers/risks, and strategic planning issues.MethodologyThe report is based on a combination of primary and secondary information sources, including interviews with laboratory directors, and executives of leading diagnostics companies and start-up firms developing innovative products in the U.S., five major European countries and Japan. In addition to primary sources of information, a comprehensive review ofthe most recent technical and business publications, manufacturer productand financial literature, as well as Venture Planning Group’s proprietary data files was conducted.

Get your copy of this report @ http://www.reportsnreports.com/reports/190562-future-horizons-in-the-global-enteric-disease-market.html

Report Details:
Published: August 2012
No. of Pages: 389
Price:Single User license:US$9800           Corporate User License:US$21500



Table Of Contents

Worldwide Market and Technology Overview
A. Major Infectious Disease Tests
1. Campylobacter
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
2. Cryptosporidium
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
3. E. Coli
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
4. Enteroviruses
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
5. RhinoViruses
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
6. RotaVirus (REOVIRUS)
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
7. Salmonellosis
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
8. Shigellosis
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
9. Vibrio
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
10. Yersinia
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
B. Instrumentation Review of Leading Analyzers Marketed by Abbott, Beckman Coulter/Danaher, BioMerieux, Ortho-Clinical Diagnostics, Roche, Siemens, Tosoh, Wallac and Other Suppliers
C. Emerging Diagnostic Technologies
1. Molecular Diagnostics
2. Monoclonal Antibodies
3. Immunoassays
4. Differential Light Scattering
5. Information Technology
6. Artificial Intelligence
7. Liposomes
8. Flow Cytometry
9. Chromatography
10. Diagnostic Imaging
11. Gel Microdroplets
12. Other

III. France: Market Size, Growth and Major Suppliers’ Sales and Market Shares

IV. Germany: Market Size, Growth and Major Suppliers’ Sales and Market Shares

V. Italy: Market Size, Growth and Major Suppliers’ Sales and Market Shares

VI. Japan: Market Size, Growth and Major Suppliers’ Sales and Market Shares

VII. Spain: Market Size, Growth and Major Suppliers’ Sales and Market Shares

VIII. UK: Market Size, Growth and Major Suppliers’ Sales and Market Shares

IX. USA: Market Size, Growth and Major Suppliers’ Sales and Market Shares
Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges Competitive Assessments

Global Business Survey: Revenue Growth Trends and Key Markets for Growth in 2012-2013

Global Business Survey: Revenue Growth Trends and Key Markets for Growth in 2012-2013” is a new report by ICD Research that provides the reader with a definitive analysis of global revenue growth outlook across 12 key industry segments in 2012-2013. The report explores projections surrounding revenue growth activities and the core factors influencing such anticipations. Additionally, the report provides the reader an analysis of the most promising emerging and developed markets across 11 key industry segments in 2012-2013. The report also provides access to information categorized by region, company type, and company size.

Introduction and Landscape

Why was the report written?

This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading global industry executives. The report provides data and analysis on global revenue growth outlook in 2012-2013 across 12 key industry segments including the key emerging and developed markets for growth. The key industries covered in this report include Airports, Beverages, Defense, Food, Medical Devices, Mining, Oil and Gas, Packaging, Pharmaceutical, Power, and Transport. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry. In an effort to bridge this gap, ICD Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value-chain of 12 key industry segments.

What is the current market landscape and what is changing?

Of respondents across various industry verticals, 58% of respondents from the global food industry are 'more optimistic’ about revenue growth of their companies in 2012. Furthermore, 55% and 53% of respondents from the global oil and gas industry and medical device industry respectively are 'more optimistic’ about the revenue growth of their companies in 2012.

Buy your copy of this report @ http://www.reportsnreports.com/reports/166257-global-business-survey-revenue-growth-trends-and-key-markets-for-growth-in-2012-2013.html

Report Details:
Published: June 2012
No. of Pages: 295
Price: Single User License:US$2000 Corporate User License: US$4000



What are the key drivers behind recent market changes?

The reasons for the increased revenue growth optimism highlighted by respondents from the global food, oil and gas, and medical device industries are increased consumer demand for health and wellness oriented food products in markets such as China and India, the emergence of new profitable markets for the oil and gas industries, growing populations, significant private-sector investments, and government support in the form of significant spending in the global medical device industry, and these are positive factors for the future growth of these industries.

What makes this report unique and essential to read?

This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading global industry executives. The report provides data and analysis on the global revenue growth outlook in 2012-2013 across 12 key industry segments including the key emerging and developed markets for growth. The key industries covered in this report include Airports, Beverages, Defense, Food, Medical Devices, Mining, Oil and Gas, Packaging, Pharmaceutical, Power, and Transport. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry. In an effort to bridge this gap, ICD Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value-chain of 12 key industry segments.

Key Features and Benefits

Project industry trends and revenue growth expectations in 2012 and make informed business decisions.

Drive revenues by understanding key investment areas and key growth regions.

Helps in identifying important markets in developing and developed regions, which will help the reader to make vital business decisions regarding business expansion.

Key Market Issues

The majority of respondents from the global food industry are 'more optimistic’ about the revenue growth of their companies in 2012. Similar trends are observed oil and gas, and the medical device industry.

The reasons for increased revenue growth highlighted by respondents from various industries are increased consumer demand towards health and wellness oriented food products in markets such as China and India, the emergence of new profitable markets for oil and gas industries, growing populations, significant private-sector investments, and government support in the form of significant spending.

Across all industries, respondents identify India, China, and Brazil as the most promising emerging markets, followed by the Middle East and Eastern Europe.

Across all industries, respondents identify Singapore, Taiwan and Hong Kong, the US, and Australia as the most promising developed regions to offer significant growth opportunities in 2012.

Key Highlights

Of respondents across various industry verticals, 58% of respondents from the global food industry are 'more optimistic’ about the revenue growth of their companies in 2012.

Survey results show that 55% and 53% of respective respondents from the global oil and gas industry and the medical devices industry are 'more optimistic’ about the revenue growth of their companies in 2012.

Across all industries, a significant portion of respondents identify India, China, and Brazil as key emerging markets in 2012. Singapore, Taiwan and Hong Kong, the US, and Australia as the most promising developed regions to offer significant growth opportunities in 2012, as identified by a large proportion of respondents across 11 key industry segments.

According to survey results, respondents from the global defense and beverage industries are 'less optimistic’ about the revenue growth of their companies in 2012.

Survey results show that 35% of respondents from the global packaging industry are 'neutral’ regarding their company’s revenue growth in 2012.

Table Of contents

1 Introduction
1.1 What is this Report About?
1.2 Methodology

2 Executive Summary

3 Global Airports Industry Outlook
3.1 Profile of Survey Respondents
3.2 Revenue Growth Trends in the Global Airports Industry
3.2.1 Revenue growth expectations by company type
3.2.2 Revenue growth expectations by region
3.2.3 Revenue growth expectations by company turnover
3.2.4 Revenue growth expectations by senior level respondents
3.3 Global Airports Industry: Demand in Emerging Markets
3.3.1 Demand in emerging markets by buyers
3.3.2 Demand in emerging markets by suppliers
3.3.3 Demand in emerging markets by region
3.3.4 Demand in emerging markets by company turnover
3.4 Global Airports Industry: Growth Projections in Developed Countries
3.4.1 Growth projections in developed countries by buyers
3.4.2 Growth projections in developed countries by suppliers
3.4.3 Growth projections in developed countries by region
3.4.4 Growth projections in developed countries by company turnover

4 Global Beverage Industry Outlook
4.1 Profile of Survey Respondents
4.2 Global Beverage Manufacturers’ Industry: Demand in Emerging Markets
4.2.1 Revenue growth expectations by beverage manufacturers
4.2.2 Revenue growth expectations by suppliers
4.2.3 Revenue growth expectations by region
4.2.4 Revenue growth expectations by company turnover
4.2.5 Revenue growth expectations by senior level respondents
4.1 Global Beverage Manufacturers’ Industry: Demand in Emerging Markets
4.1.1 Demand in emerging markets by beverage manufacturers
4.1.2 Demand in emerging markets by suppliers
4.1.3 Demand in emerging markets by region
4.1.4 Demand in emerging markets by company turnover
4.2 Global Beverage Industry: Growth Projections in Developed Markets
4.2.1 Growth projections in developed countries by beverage manufacturers
4.2.2 Growth projections in developed countries by suppliers
4.2.3 Growth projections in developed countries by region
4.2.4 Growth projections in developed countries by company turnover

5 Global Defense Suppliers’ Industry Outlook
5.1 Profile of Survey Respondents
5.2 Revenue Growth Trends in the Global Defense Suppliers’ Industry
5.2.1 Revenue growth expectations by company type
5.2.2 Revenue growth expectations by region
5.2.3 Revenue growth expectations by turnover
5.2.4 Revenue growth expectations of senior level respondents
5.3 Global Defense Suppliers’ Industry: Demand in Emerging Markets
5.3.1 Demand in emerging markets by company type
5.3.2 Demand in emerging markets by region
5.3.3 Demand in emerging markets by company turnover
5.4 Global Defense Suppliers’ Industry: Growth Projections in Developed Markets
5.4.1 Growth projections in developed markets by company type
5.4.2 Growth projections in developed countries by region
5.4.3 Growth projections in developed countries by company turnover

6 Global Food Industry Outlook
6.1 Profile of Survey Respondents
6.2 Revenue Growth Trends in the Global Food Industry
6.2.1 Revenue growth expectations by food manufactures
6.2.2 Revenue growth expectations by suppliers
6.2.3 Revenue growth expectations by region
6.2.4 Revenue growth expectations by turnover
6.2.5 Revenue growth expectations by senior level respondents
6.3 Global Food Manufacturers’ Industry: Demand in Emerging Markets
6.3.1 Demand in emerging markets by food manufacturers
6.3.2 Demand in emerging markets by suppliers
6.3.3 Demand in emerging markets by region
6.3.4 Demand in emerging markets by company turnover
6.4 Global Food Manufacturers’ Industry: Growth Projections in Developed Countries
6.4.1 Growth projections in developed countries by food manufacturers
6.4.2 Growth projections in developed countries by suppliers
6.4.3 Growth projections in developed countries by region
6.4.4 Growth projections in developed countries by company turnover

7 Global Medical Devices Industry Outlook
7.1 Profile of Survey Respondents
7.2 Revenue Growth Trends in the Global Medical Devices Industry
7.2.1 Revenue growth expectations by company type
7.2.2 Revenue growth expectations by region
7.2.3 Revenue growth expectations by turnover
7.2.4 Revenue growth expectations by senior-level respondents
7.3 Global Medical Devices Industry: Demand in Emerging Markets
7.3.1 Demand in emerging markets by buyers
7.3.2 Demand in emerging markets by suppliers
7.3.3 Demand in emerging markets by region
7.3.4 Demand in emerging markets by company turnover
7.4 Global Medical Devices industry: Growth Projections in Developed Countries
7.4.1 Growth projections in developed countries by buyers
7.4.2 Growth projections in developed countries by suppliers
7.4.3 Growth projections in developed countries by region
7.4.4 Growth projections in developed countries by company turnover

8 Global Mining Industry Outlook
8.1 Profile of Survey Respondents
8.2 Revenue Growth Trends in the Global Mining Industry
8.2.1 Revenue growth expectations by company type
8.2.2 Revenue growth expectations by region
8.2.3 Revenue growth expectations by turnover
8.2.4 Revenue growth expectations by senior level respondents
8.3 Global Mining Industry: Demand in Emerging Markets
8.3.1 Demand in emerging markets by buyers
8.3.2 Demand in emerging markets by suppliers
8.3.3 Demand in emerging markets by region
8.3.4 Demand in emerging markets by company turnover
8.4 Global Mining Industry: Growth Projections in Developed Countries
8.4.1 Growth projections in developed countries by buyers
8.4.2 Growth projections in developed countries by suppliers
8.4.3 Growth projections in developed countries by region
8.4.4 Growth projections in developed countries by company turnover

9 Global Oil and Gas Industry Outlook
9.1 Profile of Survey Respondents
9.2 Revenue Growth Trends in the Global Oil and Gas Industry
9.2.1 Revenue growth expectations by company type
9.2.2 Revenue growth expectations by region
9.2.3 Revenue growth expectations by turnover
9.2.4 Revenue growth expectations by senior level respondents
9.3 Global Oil and Gas Industry: Demand in Emerging Markets
9.3.1 Demand in emerging markets by buyers
9.3.2 Demand in emerging markets by suppliers
9.3.3 Demand in emerging markets by region
9.3.4 Demand in emerging markets by company turnover
9.4 Global Oil and Gas Industry: Growth Projections in Developed Markets
9.4.1 Growth projections in developed markets by buyers
9.4.2 Growth projections in developed markets by suppliers
9.4.3 Growth projections in developed markets by region
9.4.4 Growth projections in developed markets by company turnover

10 Global Packaging Industry Outlook
10.1 Profile of Survey Respondents
10.2 Revenue Growth Trends in the Global Packaging Industry
10.2.1 Revenue growth expectations by company type
10.2.2 Revenue growth expectations by region
10.2.3 Revenue growth expectations by turnover
10.2.4 Revenue growth expectations by senior-level respondents
10.3 Global Packaging Industry: Demand in Emerging Markets
10.3.1 Demand in emerging markets by buyers
10.3.2 Demand in emerging markets by suppliers
10.3.3 Demand in emerging markets by region
10.3.4 Demand in emerging markets by company turnover
10.4 Global Packaging industry: Growth Projections in Developed Markets
10.4.1 Growth projections in developed countries by buyers
10.4.2 Growth projections in developed countries by suppliers
10.4.3 Growth projections in developed countries by region
10.4.4 Growth projections in developed countries by company turnover

11 Global Pharmaceutical Industry Outlook
11.1 Profile of Survey Respondents
11.2 Revenue Growth Trends in the Global Pharmaceutical Industry
11.2.1 Revenue growth expectations by company type
11.2.2 Revenue growth expectations by region
11.2.3 Revenue growth expectations by turnover
11.2.4 Revenue growth expectations by senior level respondents
11.3 Global Pharmaceutical Industry: Demand in Emerging Markets
11.3.1 Demand in emerging markets by buyers
11.3.2 Demand in emerging markets by suppliers
11.3.3 Demand in emerging markets by region
11.3.4 Demand in emerging markets by company turnover
11.4 Global Pharmaceutical Industry: Growth Projections in Developed Countries
11.4.1 Growth projections in developed countries by buyers
11.4.2 Growth projections in developed countries by suppliers
11.4.3 Growth projections in developed countries by region
11.4.4 Growth projections in developed countries by company turnover

12 Global Power Industry Outlook
12.1 Profile of Survey Respondents
12.2 Revenue Growth Trends in the Global Power Industry
12.2.1 Revenue growth expectations by company type
12.2.2 Revenue growth expectations by region
12.2.3 Revenue growth expectations by turnover
12.2.4 Revenue growth expectations by senior level respondents
12.3 Global Power Industry: Demand in Emerging Markets
12.3.1 Demand in emerging markets by buyers
12.3.2 Demand in emerging markets by suppliers
12.3.3 Demand in emerging markets by region
12.3.4 Demand in emerging markets by company turnover
12.4 Global Power Industry: Growth Projections in Developed Countries
12.4.1 Growth projections in developed countries by buyers
12.4.2 Growth projections in developed countries by suppliers
12.4.3 Growth projections in developed countries by region
12.4.4 Growth projections in developed countries by company turnover

13 Global Transport Industry Outlook
13.1 Profile of Survey Respondents
13.2 Revenue Growth Trends in the Global Transport Industry
13.2.1 Revenue growth projections by buyers
13.2.2 Revenue growth projections by suppliers
13.2.3 Revenue growth expectations by region
13.2.4 Revenue growth expectations by company turnover
13.2.5 Revenue growth expectations by senior level respondents
13.3 Global Transport Industry: Demand in Emerging Markets
13.3.1 Demand in emerging markets by buyers
13.3.2 Demand in emerging markets by suppliers
13.3.3 Demand in emerging markets by region
13.3.4 Demand in emerging markets by company turnover
13.4 Global Transport Industry: Growth Projections in Developed Countries
13.4.1 Growth projections in developed countries by buyers
13.4.2 Growth projections in developed countries by suppliers
13.4.3 Growth projections in developed countries by region
13.4.4 Growth projections in developed countries by company turnover

14 Appendix
14.1 Survey Results
14.2 Methodology
14.3 Contact us
14.4 About ICD Research
14.5 Disclaimer

List Of Tables

Table 1: Revenue Growth Optimism: Cross Industry Comparison (%), 2012 16
Table 2: Global Airports Industry Survey Respondents by Company Type, 2012 18
Table 3: Global Airports Industry Revenue Growth Optimism (%), 2010-2012 19
Table 4: Global Airports Industry Revenue Growth Optimism by Buyers (%), 2010-2012 21
Table 5: Global Airports Industry Revenue Growth Optimism by Suppliers (%), 2010-2012 21
Table 6: Global Airports Industry Revenue Growth Optimism by Region (%), 2010-2012 23
Table 7: Global Airports Industry Revenue Growth Optimism by Turnover (%), 2012 25
Table 8: Global Airports Industry Revenue Growth Optimism by Senior Level Respondents (%), 2012 26
Table 9: Demand in Emerging Markets by Global Airport Operators (%), 2012 29
Table 10: Demand in Emerging Markets by Global Airport Support Services (%), 2012 31
Table 11: Demand in Emerging Markets by Global Airports Industry Suppliers (%), 2012 33
Table 12: Growth Projections in Developed Countries by Global Airport Operators (%), 2012 38
Table 13: Growth Projections in Developed Countries by Global Airport Support Services (%), 2012 39
Table 14: Growth Projections in Developed Countries by Global Airports Industry Suppliers (%), 2012 41
Table 15: Total Global Beverage Manufacturers' Industry Survey Respondents, 2012 44
Table 16: Revenue Growth Optimism in the Global Beverage Manufacturers' Industry (%), 2010-2012 45
Table 17: Revenue Growth Optimism of Global Beverage Industry Suppliers (%), 2012 46
Table 18: Global Beverage Manufacturers' Industry: Revenue Growth Optimism by Region (%), 2012 47
Table 19: Global Beverage Manufacturers’ Industry: Revenue Growth Optimism by Turnover (%), 2012 48
Table 20: Global FandB Industry: Revenue Growth Optimism of Senior Level Respondents (%), 2012 49
Table 21: Demand in Emerging Markets: Global Beverage Manufacturers' Industry (%), 2012 52
Table 22: Demand in Emerging Markets: Global Beverage Industry Suppliers (%), 2012 53
Table 23: Growth Projections in Developed Markets: Global Beverage Manufacturers (%), 2012 59
Table 24: Growth Projections in Developed Markets by Global Beverage Industry Suppliers (%), 2012 60
Table 25: Global Defense Suppliers’ Industry Respondents by Company Type, 2012 64
Table 26: Global Defense Suppliers’ Industry: Revenue Growth Optimism (%), 2011-2012 65
Table 27: Global Defense Suppliers’ Industry: Revenue Growth Expectations by Region (%), 2012 69
Table 28: Global Defense Suppliers’ Industry: Revenue Growth Expectations by Turnover (%), 2012 70
Table 29: Revenue Growth Expectations by Senior Level Respondents (%), 2012 71
Table 30: Demand in Emerging Markets by Global Defense Contractors (%), 2012 74
Table 31: Demand in Emerging Markets: Global Defense Industry Other Service Providers (%), 2012 75
Table 32: Growth in Developed Countries: Global Defense Industry Other Service Providers (%), 2012 82
Table 33: Total Global Food Manufacturers’ Industry Survey Respondents, 2012 85
Table 34: Revenue Growth Optimism in the Global Food Manufacturers' Industry (%), 2010-2012 86
Table 35: Revenue Growth Optimism by Global Food Industry Suppliers (%), 2012 88
Table 36: Revenue Growth Optimism in the Global Food Manufacturers' Industry by Region (%), 2012 89
Table 37: Revenue Growth Optimism in the Global Food Manufacturers’ Industry by Turnover (%), 2012 90
Table 38: Revenue Growth Optimism by Senior Level Respondents: Global Food Manufacturers' Industry (%), 2012 91
Table 39: Demand in Emerging Markets by Global Food Manufacturers' Industry (%), 2012 94
Table 40: Demand in Emerging Markets by Global Food Industry Suppliers (%), 2012 96
Table 41: Growth Projections in Developed Countries by Global Food Manufacturers' Industry (%), 2012 101
Table 42: Growth Projections in Developed Countries by Global Food Industry Suppliers (%), 2012 103
Table 53: Total Global Medical Devices Industry Survey Respondents by Company Type, 2012 107
Table 54: Global Medical Devices Industry Revenue Growth Optimism (%), 2010-2012 108
Table 55: Global Medical Devices Industry Revenue Growth Optimism by Company Type(%), 2010-2012 110
Table 56:Global Medical Devices Industry Revenue Growth Optimism by Region (%), 2010-2012 111
Table 57: Global Medical Devices Industry Revenue Growth Optimism by Turnover (%), 2012 113
Table 58: Global Medical Devices Industry Revenue Growth Optimism by Senior-Level (%), 2012 114
Table 59: Demand in Emerging Markets by Global Medical Devices Manufacturers(%), 2012 117
Table 60: Demand in Emerging Markets by Global Medical Devices Industry Suppliers(%), 2012 119
Table 61: Growth in Developed Countries: Global Medical Devices Manufacturers (%), 2012 124
Table 62: Growth in Developed Countries by Global Medical Devices Industry Suppliers (%), 2012 125
Table 63: Total Global Mining Industry Survey Respondents by Company Type, 2012 129
Table 64: Revenue Growth Optimism in the Global Mining Industry(%), 2010-2012 130
Table 65: Revenue Growth Optimism in the Global Mining Industry by Buyers (%), 2010-2012 131
Table 66: Revenue Growth Optimism in the Global Mining Industry by Suppliers (%), 2010-2012 131
Table 67: Revenue Growth Optimism in the Global Mining Industry by Region (%), 2010-2012 133
Table 68: Revenue Growth Optimism in the Global Mining Industry by Turnover (%), 2012 134
Table 69: Revenue Growth Optimism by Senior Level Respondents: Global Mining Industry(%), 2012 135
Table 70: Global Mining Industry: Demand in Emerging Markets by Buyers (%), , 2012 138
Table 71: Global Mining Industry: Demand in Emerging Markets by Suppliers (%), 2012 140
Table 72: Global Mining Industry: Growth Projections in Developed Countries by Buyers (%), 2012 146
Table 73: Global Mining Industry: Growth Projections in Developed Countries by Suppliers (%), 2012 147
Table 74: Global Oil and Gas Industry Survey Respondents by Company Type, 2012 151
Table 75: Revenue Growth Optimism in the Global Oil and Gas Industry (%), 2012 152
Table 76: Revenue Growth Optimism in the Global Oil and Gas Industry by Company Type (%), 2012 153
Table 77: Revenue Growth Optimism in the Global Oil and Gas Industry by Region (%), 2009-2012 155
Table 78: Revenue Growth Optimism in the Global Oil and Gas Industry by Turnover (%), 2012 156
Table 79: Revenue Growth Optimism in the Global Oil and Gas Industry by Senior Respondents (%), 2012 157
Table 80: Demand in Emerging Markets: Upstream Oil and Gas Companies (%), 2012 160
Table 81: Demand in Emerging Markets: Downstream and Midstream Oil and Gas Companies (%), 2012 161
Table 82: Global Oil and Gas Industry: Demand in Emerging Markets by Suppliers (%), 2012 162
Table 83: Growth Projections in Developed Markets: Upstream Oil and Gas Companies (%), 2012 167
Table 84: Growth Projections in Developed Markets: Downstream and Midstream Oil and Gas Companies (%), 2012 168
Table 85: Global Oil and Gas Industry: Growth Projections in Developed Markets by Suppliers (%), 2012 170
Table 86: Total Global Packaging Industry Survey Respondents by Company Type, 2012 173
Table 87: Global Packaging Industry Revenue Growth Optimism (%), 2010-2012 174
Table 88: Global Packaging Industry Revenue Growth Optimism by Company Type (%), 2010-2012 175
Table 89:Global Packaging Industry Revenue Growth Optimism by Region (%), 2010-2012 177
Table 90: Global Packaging Industry Revenue Growth Optimism by Turnover (%), 2012 178
Table 91: Global Packaging Industry Revenue Growth Optimism: Senior-Level Respondents (%), 2012 179
Table 92: Demand in Emerging Markets by Global Packaging Buyers(%), 2012 183
Table 93: Growth in Developed Countries: Global Packaging Buyers (%), 2012 189
Table 94: Growth in Developed Countries by Global Packaging Suppliers (%), 2012 190
Table 95: Total Global Pharmaceutical Industry Survey Respondents by Company Type, 2012 194
Table 96: Global Pharmaceutical Industry Revenue Growth Optimism (%), 2010-2012 195
Table 97: Global Pharmaceutical Industry Revenue Growth Optimism by Buyers (%), 2010-2012 197
Table 98: Global Pharmaceutical Industry Revenue Growth Optimism by Region (%), 2010-2012 199
Table 99: Global Pharmaceutical Industry Revenue Growth Optimism by Turnover (%), 2012 201
Table 100: Global Pharmaceutical Industry Revenue Growth Optimism by Senior Level (%), 2012 202
Table 101: Demand in Emerging Markets by Global Pharmaceutical Manufacturers (%), 2012 205
Table 102: Demand in Emerging Markets by Global CRO and CMO Industry (%), 2012 206
Table 103: Demand in Emerging Markets by Global Pharmaceutical Industry Suppliers (%), 2012 208
Table 104: Growth in Developed Countries: Global Pharmaceutical Manufacturers (%), 2012 213
Table 105: Growth Expectations in Developed Countries by Global CRO and CMO Respondents(%), 2012 215
Table 106: Growth Expectations in Developed Countries by Global Pharmaceutical Industry Suppliers (%), 2012 216
Table 107: Global Power Industry Survey Respondents by Company Type, 2012 220
Table 108: Revenue Growth Optimism in the Global Power Industry by Buyers (%), 2009-2012 221
Table 109: Revenue Growth Optimism in the Global Power Industry by Suppliers (%), 2009-2012 221
Table 110: Revenue Growth Optimism in the Global Power Industry by Region (%), 2009-2012 223
Table 111: Revenue Growth Optimism in the Global Power Industry by Turnover (%), 2012 225
Table 112: Revenue Growth Optimism in the Global Power Industry by Senior Respondents (%), 2012 226
Table 113: Demand in Emerging Markets: Fossil Fuel Power Generators(%), 2012 228
Table 114: Demand in Emerging Markets: Alternative Power Generators(%), 2012 230
Table 115: Global Power Industry: Demand in Emerging Markets by Suppliers (%), 2012 232
Table 116: Growth Projections in Developed Countries: Fossil Fuel Power Generators (%), 2012 238
Table 117: Growth Projections in Developed Countries: Alternative Power Generation Companies (%), 2012 239
Table 118: Global Power Industry: Growth Projections in Developed Countries by Suppliers (%), 2012 241
Table 119: Global Transport Industry Survey Respondents by Company Type, 2012 245
Table 120: Global Transport Industry Revenue Growth Optimism (%), 2010-2012 245
Table 121: Global Transport Industry: Revenue Growth Optimism by Buyers (%), 2010-2012 247
Table 122: Global Transport Industry: Revenue Growth Optimism by Suppliers (%), 2010-2012 249
Table 123: Global Transport Industry: Revenue Growth Optimism by Region (%), 2012 250
Table 124: Global Transport Industry: Revenue Growth Optimism by Turnover (%), 2012 251
Table 125: Global Transport Industry: Revenue Growth Optimism by Senior Level Respondents (%), 2012 252
Table 126: Demand in Emerging Markets: Global Rail Industry Buyers (%), 2012 253
Table 127: Demand in Emerging Markets: Global Road Industry Buyers (%), 2012 255
Table 128: Demand in Emerging Markets: Global Ship Industry Buyers (%), 2012 257
Table 129: Global Transport Industry: Demand in Emerging Markets by Suppliers (%), 2012 258
Table 130: Growth Projections in Developed Countries: Global Rail Industry Buyers (%), 2012 262
Table 131: Growth Projections in Developed Countries: Global Road Industry Buyers (%), 2012 264
Table 132: Growth Projections in Developed Countries: Global Ship Industry Buyers (%), 2012 265
Table 133: Global Transport Industry: Growth Projections in Developed Markets by Suppliers (%), 2012 266
Table 134: Global Industry Survey Results 270

Treatment Algorithms: Schizophrenia – New antipsychotic launches underwhelm

Psychiatrists estimate that just under half of prevalent schizophrenia cases do not report their symptoms and seek treatment, while one third of patients do not receive an accurate diagnosis. The nature of schizophrenia complicates its presentation, as sufferers may lack the drive or insight into their symptoms needed to seek help.
Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka) is the most commonly used antipsychotic brand for first- and second-line treatment of schizophrenia. In a market where treatment decisions are largely driven by safety profiles, Abilify is crucially associated with lower incidences of common antipsychotic side effects than some of its competitors.
The three latest antipsychotics to reach the market have all experienced very slow uptake and have so far failed to penetrate first-line therapy. Their underwhelming market shares reveal that the US schizophrenia drug market is now saturated with atypical antipsychotics and that the market not very receptive to new, undifferentiated treatments.

Your key questions answered

• How does each drug’s patient share vary by country and line of therapy?
• What can be done to influence the patient pathway to increase market share?
• What is the realistic patient population that a new market entrant can target?
• How have generic antipsychotics affected prescribing behaviors in the seven major markets?
• What proportion of patients experience treatment a complete response with currently available antipsychotics?

Buy your copy of report @ http://www.reportsnreports.com/reports/160647-treatment-algorithms-schizophrenia-new-antipsychotic-launches-underwhelm.html   

Report Details

Published: May 2012
No. of Pages: 81
 Price: Single User License:US $ 7600        Corporate User License: US $ 19000

  

Table of Contents
OVERVIEW
Catalyst
Summary
EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor key findings
Related reports
COUNTRY TREATMENT TREES
Introduction to treatment trees
Seven major markets
US
Japan
France
Germany
Italy
Spain
UK
DISEASE DEFINITION AND DIAGNOSIS
Disease definition
Etiology
Environmental risk factors
Genetic risk factors
Pathophysiology of schizophrenia
Symptoms
Schizophrenia is typified by positive, negative, and cognitive symptoms
Presentation and diagnosis
Just over one in two prevalent schizophrenia sufferers report symptoms and seek treatment
One third of prevalent schizophrenia patients are either undiagnosed or misdiagnosed
Treatment rates
Schizophrenia has a higher pharmacological treatment rate than other common psychiatric disorders
Referral patterns
Schizophrenia is largely managed in specialist care
The Japanese referral pathway differs to those in the US and Europe
 

Treatment Algorithms: Dyslipidemia – Statin monotherapies dominate the market but uncontrolled lipid levels remain an issue

Datamonitor estimates the antidyslipidemic drug-treated population at 73.5 million patients across the seven major markets, with the majority having high cholesterol as opposed to hypertriglyceridemia alone. Statins are the dominant treatment for high cholesterol while fibrates are more used for hypertriglyceridemia. Lipid control is an unmet need in a high proportion of drug-treated patients.

Features and benefits

• Follow patient segmentation and treatment pathways for dyslipidemia across the seven major markets.
• Gain insight into the most commonly used therapies for pure hypercholesterolemia, pure hypertriglyceridemia, and mixed hyperlipidemia.
• Understand prescribing trends and their affect on treatment regimens.
• Identify unmet needs, especially within dyslipidemic sub-populations, which represent market opportunities.
• Understand the impact of generic entry on the antidyslipidemic market.

Highlights

Not all patients are available for drug therapy due to the low diagnosis rate, low compliance rates, and therapeutic lifestyle management as the first line of treatment. Only 43% of dyslipidemia patients are reported diagnosed within the seven major markets.

The type of dyslipidemia that a patient is diagnosed with impacts on the treatment regimen used. Statin monotherapy dominates where the target lipid is low-density lipoprotein cholesterol. This is due to statins’ superior proven efficacy in lowering both target lipid levels and cardiovascular disease risk.

Get Your Copy of Report @ http://www.reportsnreports.com/reports/160352-treatment-algorithms-dyslipidemia-statin-monotherapies-dominate-the-market-but-uncontrolled-lipid-levels-remain-an-issue.html 

Report Details :
Published: May 2012
No. of Pages: 69
 Price: Single User License: US $ 7600 Corporate User License : US $ 17000

    

Table Of Contents

OVERVIEW
Catalyst
Summary

EXECUTIVE SUMMARY
Datamonitor key findings
Related reports

TREATMENT ALGORITHMS AND PATIENT PROFILES
Methodology
Patient profiles: seven major markets
Treatment algorithm: seven major markets

DISEASE DEFINITION AND DIAGNOSIS
Disease definition
Etiology
Lifestyle is the most common cause of dyslipidemia
Prognosis
Dyslipidemia is generally asymptomatic, but it can lead to symptomatic cardiovascular disease
Presentation and diagnosis
As an asymptomatic disease, country-wide screening is recommended to limit cardiovascular risk
Over half of dyslipidemia patients are undiagnosed
Treatment rates
Lifestyle management effectiveness is limited by under-prescription and low compliance
Variations in treatment guidelines affect reported treatment rates
Reported compliance rates vary considerably across the seven major markets

PATIENT SEGMENTATION
Segmentation by lipid levels
Pure hypertriglyceridemia is less common than cholesterol-related dyslipidemias
High-density lipoprotein cholesterol
Familial hypercholesterolemia

CURRENT TREATMENT OPTIONS
Overview of the antidyslipidemic drug classes
Prescribing trends
Prescription trends for specific dyslipidemia subgroups are based on antidyslipidemic class efficacy
Class usage across the seven markets is largely consistent
Prescribing strategies
Therapy switching is most commonly due to insufficient lipid modulation
Generic antidyslipidemics continue to take market share from key brands following Lipitor's patent expiry

PRESCRIBING INFLUENCES AND UNMET NEEDS
Prescribing influences
(Untitled sub-section)
Treatment outcomes: unmet needs
Physicians’ highest priority unmet needs: antidyslipidemics with stronger efficacy at improving lipid deviations

BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports 



 

Therapy Trends: Multiple Sclerosis

An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse future trends.

Driven by in-depth interviews with the world’s leading multiple sclerosis KOLs, Therapy Trends: Multiple Sclerosis uncovers how the current treatment landscape will be impacted by significant future events, with particular focus on pipeline therapies and how these will modify the way MS is managed by neurologists in the future.

Reasons to Buy

The deliverables

Therapy Trends: Multiple Sclerosis is delivered in two complimentary formats:

Therapy Trends Intelligence Report: a concise, focused, in-depth market intelligence research report that examines the range of current and late-stage pipeline drugs to determine future trends in the treatment and diagnosis of MS, and assess the commercial impact on the MS market landscape.

Therapy Trends Impact Assessments: dynamic analyst briefings evaluating the impact of events in the MS market over the next 12 months, delivered to you within days of a significant event happening

Key Benefits

• Unmet needs analysis to identify opportunities and address the challenges facing disease management
• Strategic mapping of future treatment algorithms based on KOL insight
• Commercial and clinical analysis of pipeline therapies
• In-depth, dynamic event impact assessments to evaluate current strategies and plans against new conditions
• Align investment and resource planning to future trends
• Know the story driving the trends

Multiple Sclerosis Therapy Trends

Published: April 2012
No. of Pages: 160
Price: Single User License: US $ 4995 Corporate User License : US $ 14995

  


Executive Summary
Introduction
Methodology
Current multiple sclerosis marketplace
> Current treatment landscape
> Multiple sclerosis market definition
> Current market overview
> Current therapies
> Cross trial comparisons is not an ideal assessment
> Gilenya (fingolimod; Novartis) trends
> Gilenya has first oral to market advantage
> Gilenya raises bar for pipeline therapies entering the market
> Deaths mar Gilenya's side effect profile and positions drug as a second line
> Vigilance program is cumbersome and likely to restrict access
> Gilenya's high price will restrict use
> Clinical trials in progressive multiple sclerosis ongoing
> Tysabri (natalizumab; Biogen/Elan) trends
> Tysabri is the most effective approved multiple sclerosis therapy
> PML fears positions drug as second or later line
> JCV test will promote use and allay fears
> Progressive multiple sclerosis trials ongoing for Tysabri
> Copaxone (glatiramer acetate; Teva) trends
> Copaxone is the leading selling multiple sclerosis therapy
> Teva fights generic Copaxone applications
> Interferon betas (Avonex, Betaseron, Rebif, Extavia) trends
> Interferons are the mainstay of multiple sclerosis treatment
> Needles have evolved to avoid injection site reactions
> Biosimilar guidelines in place for interferons
> Current treatment algorithm
> Multiple sclerosis unmet needs
> Unmet need 1: Efficacy for progressive subtypes
> Unmet need 2: Therapies offering better clinical profiles
> Unmet need 3: Drugs to halt or repair neuronal damage
> Unmet need 4: Improving multiple sclerosis induced cognition dysfunction
> Unmet need 5: Need for improved adherence

Browse more Pharmaceutical Reports @ http://www.reportsnreports.com/market-research/pharmaceuticals/

Erythropoietin Market in Japan 2011-2015

TechNavio's analysts forecast the Erythropoietin market in Japan to reach US$1.54 billion by 2015. One of the key factors contributing to this market growth is the increase in cases of renal anemia. The Erythropoietin market in Japan has also been witnessing the R&D activities for the application of erythropoietin in neurological disorders. However, the delayed approval process for biosimilars of erythropoietin in Japan could pose a challenge to the growth of this market.

TechNavio's report, the Erythropoietin Market in Japan 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report focuses on Japan; it also covers the Erythropoietin market in the Japan landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this market space include Chugai Pharmaceutical Co. Ltd., JCR Pharmaceuticals Co. Ltd., and Kyowa Hakko Kirin Co. Ltd.

Key questions answered in this report:

• What will the market size be in 2015 and at what rate will it grow?
• What key trends is this market subject to?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the opportunities and threats faced by each of these key vendors?
• What are the strengths and weaknesses of each of these key vendors?

Report Details:
Published: April 2012
No. of Pages: 30
Price: Single User License: US $ 1500 Corporate User License : US $ 2500

 

Request a Sample @ http://www.reportsnreports.com/reports/157685-erythropoietin-market-in-japan-2011-2015.html

2011-2015 Global MEMS Accelerometer Market

TechNavio’s analysts forecast the Global MEMS Accelerometer market to grow at a CAGR of 17.5 percent over the period 2011–2015. One of the key factors contributing to this market growth is the declining price of MEMS accelerometers. The Global MEMS Accelerometer market has also been witnessing an increasing number of MEMS accelerometer applications in safeguarding laptop hard disks. However, the high cost of production could pose a challenge to the growth of this market.

TechNavio’s report, the Global MEMS Accelerometer Market 2011–2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global MEMS Accelerometer market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

MEMS Accelerometer Market

Published: March 2012
No. of Pages: 33
Price: Single User License: US$ 1500     Corporate User License: US$2500

 

Key questions answered in this report:

* What will the market size be in 2015 and at what rate will it grow?
* What key trends is this market subject to?
* What is driving this market?
* What are the challenges to market growth?
* Who are the key vendors in this market space?
* What are the opportunities and threats faced by each of these key vendors?
* What are the strengths and weaknesses of each of these key vendors?

Few points from Table of Contents
Table Of contents

01. Executive Summary

02. Introduction

03. Market Coverage

04. Market Landscape

05. Geographical Segmentation

06. Vendor Landscape

07. Buying Criteria

08. Market Growth Drivers

09. Drivers and their Impact

10. Market Challenges

11. Impact of Drivers and Challenges

12. Market Trends

13. Key Vendor Analysis
13.1 STMicroelectronics N.V
13.2 Bosch Sensortec GmbH
13.3 Kionix Inc.
13.4 Freescale Semiconductor Inc.

Antibody Drugs: Technologies and Global Markets

STUDY GOALS AND OBJECTIVES

The aim of this report is to provide a range of information—from detailed analysis through industry trends—to quantify and qualify the rapidly growing market for therapeutic monoclonal antibody (mAb) drugs. Forecasts and trends are gleaned from industry sources, analyst reports, and company forecasts, as well as from assessment of available and emerging technologies.

The report develops forecasts for sales of the mAb market by individual antibody, by therapeutic antibody target (epidermal growth factor receptor [EGFR], cluster of differentiation [CD] 20, tumor necrosis factor [TNF] alpha, etc.), and by major disease applications from 2011 through 2016. Additionally, we examine strategies employed by biopharmaceutical firms to develop and market products in this explosive market sector.

Our main objective is to present a comprehensive analysis of the current market for therapeutic mAb disease-modifying products and to forecast this market’s future direction through 2016.

INTENDED AUDIENCE

This study will be of interest to those working in the biotechnology and pharmaceutical industries and related life science, drug discovery, and diagnostic test manufacturing companies, as well as all those interested or actively working in drug research.

Both individuals looking for a comprehensive listing of mAbs in human clinical-stage development and individuals looking at how the mAb drug marketplace is expected to change (in terms of sales and technology) in the coming years will find this report extremely useful.

Antibody Drugs Market

Published: February 2012
No. of Pages: 193
Price: Single User License: US$4850                        Corporate User License: US$8500

SCOPE OF REPORT

This report analyzes and assesses therapeutic applications of mAbs in human medicine. Covered in this report are mAbs exclusively, including the combination of mAbs when they are attached to a cytotoxic agent such as with ADCs.

Excluded from this report are diagnostic uses of mAbs (such as for imaging purposes) and therapeutic antibodies for veterinary use. Also excluded are research applications of mAbs.

The scope of the study is global. The “Overview” section provides a discussion of the importance and advantages of antibody-based products, valuation of antibody product sales, patent issues and differences in applicability of mAbs products versus polyclonal antibodies (pAbs), and other competing agents such as small molecule therapeutics.

The “Technology and Technical Issues” section discusses new directions in antibody research, the types of antibodies used as therapeutics, the challenges in antibody production, and other approaches—in particular transgenic sources—of antibody production.

The “Products” section provides a synopsis of more than 60 mAb drugs, including those currently marketed and those in late-stage development. Comparative product and sales analyses are provided for individual products. Tables include current and forecasted sales by individual product, sales by target and technology (for mAb-based drugs), as well as global market size and growth estimates for therapeutic mAbs.

The “Applications” section provides an overview of the leading indications for available and emerging antibody-based therapeutics. These include selected indications for autoimmune diseases (specifically rheumatoid arthritis, psoriasis, and Crohn’s disease), cancer indications (specifically the most common solid tumor types, leukemias, and lymphomas) cardiovascular diseases, infectious diseases, ophthalmic indications, and respiratory diseases.

The “Industry Structure” section provides an overview of the antibody industry as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.

The “Company Profiles” section emphasizes companies that lead the biotechnology and pharmaceutical industry in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.

Global Biosimilars: A return to optimism?

Examining the market for companies
The need for a settled market environment is essential if the growing numbers of biologic products losing patent protection in the next 5-10 years is to be exploited. However, progress is painfully slow and critical issues driving the market dynamic include:

Industry investment: a sign of confidence?
This report provides a detailed analysis of 50 companies active in the biosimilars field, many of which have declared their interest in 2011. The move may reflect a growing confidence that as regulatory provision for biosimilars increases, and as the pipeline of prospective products matures, then the prospect of actually being able to launch products grows more realistic.

The US continues to disappoint; Europe forges ahead
Despite President Obama's health reform bill being passed in 2010, very little has happened. And the FDA's cautious approach suggests little will happen in the immediate future. The much anticipated Guidance, expected in 2011 has failed to appear, and in May 2011 FDA published details for User Fees - a scheme that will not come into effect (assuming it is passed by Congress) until 2013. Given that an untried regulatory system will not operate at the fastest speed then prospects of a US market for advanced biosimilars seem remote before 2015. In contrast, European regulators are revising their widely-adopted regulations in the light of experience, with a view to issuing revisions and guidance in 2012.

Developing markets may offer a profitable alternative
Developing markets with rising disposable incomes may present the medium-term prospect for biosimilars, since they combine a large target population with reduced operating costs. Many countries are following the EU model of regulation. Markets such as India and China have plenty of home-grown production capacity. Some companies have sought to turn this capacity to their advantage, and have signed deals with Chinese/Indian producers for the development of products to be sold around the world.

Global Biosimilars Market

Published:January 2012
No. of Pages: 200




The Challenge for Industry
The development of a biosimilar presents a series of challenges to traditional generic drug manufacturers seeking to enter the sector. To succeed, a company must have good financial backing. Small companies will be able to do the science, but the cost of product development and approval will generally exceed the resources of most chemical generic organisations. After this, there is the cost of marketing and post-market surveillance. There is little prospect in the EU and USA of biosimilars being sold unbranded and biosimilar developers will have to pay for the branding and the marketing of the products; a task for which many lack the funds, sales force and experience.

Corporate manoeuvring is seeing the competitive landscape change
Despite the challenges there has been an upsurge in company activity, most notably from the branded industry and from companies who have no current significant pharmaceutical interests. With the regulatory situation generally favourable to the branded industry, why are they interested?

There are three broad reasons why an originator would wish to become involved with biosimilars. Firstly, it would create a more diversified portfolio, an important consideration in an era of near-dry pipelines. Secondly, it would potentially allow for the development of expertise in the biologic area for companies which traditionally have limited involvement in biologics. Thirdly, it could potentially act as a "spoiler" operation by making the market environment more difficult for smaller biosimilar developers.

Benchmarking The Pharmaceutical Market By Drug Delivery To 2014 Now Available At ReportsandReports

Original Source: Pharmaceutical Market

Buy Now: Market Research

Dallas, TX: ReportsandReports announce it will carry Benchmarking the Pharmaceutical Market by Drug Delivery to 2014 Market Research Report in its Store.

Drug delivery can play an important role at all stages of a drug’s lifecycle and has become an ever present feature in the business model of the leading pharmaceutical companies. Using the PharmaVitae Explorer database, the report provides an in depth sales analysis of the specific routes of administration driving the pharmaceutical market out to 2014

Scope

• Assess how drug delivery has become an ever present feature in the business model of the leading pharmaceutical companies
• Provides an insight into the prominent technology types in the expansive drug delivery segment
• Benchmarks the sales performance of the leading prescription pharmaceutical companies in terms of drug delivery

Highlights

The oral and injectable segments are the dominant routes of administration in the prescription pharmaceutical market, accounting for more than 80% of combined sales in 2008.

Injectables will see the biggest increase in annual sales at $49 billion over 200814. In contrast, oral drugs will collectively decline by $10.9 billion over the same period.

Slow-growth therapy areas are generally entrenched in oral medications. This dynamic is mirrored by the fast-growth therapy areas, where novel injectable drugs will primarily drive growth.

Reasons to Purchase

• Assess the ways in which drug delivery technology to add value to pharmaceutical products
• Determine current R&D trends in the drug delivery segment
• Examine the long-term sales performance of each delivery type across the leading prescription pharmaceutical players

TABLE OF CONTENTS

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this report

PharmaVitae Explorer database 3

Chapter structure 4

Data sourcing 4

Chapter 2 Executive summary

Key findings

Drug delivery overview 6

Prescription pharmaceutical market by delivery mechanism, 2002–14 12

Chapter 3 Overview of drug delivery market

Key findings

Introduction to drug delivery 28

Chapter 4 Segmentation of the drug delivery market

Key findings

Segmentation of the drug delivery market 35

Segmentation by mode of delivery 37

Segmentation by technology type 45

Merging technology with commercial opportunity 48

Chapter 5 Sales analysis of the pharmaceutical market by drug delivery

Key findings

A delivery-focused sales analysis of the leading prescription pharmaceutical companies 51

Prescription pharmaceutical market by delivery mechanism 53

Drug delivery analysis of the leading pharmaceutical players by company 67

Drug delivery analysis of the leading pharmaceutical players by company 74

Chapter 6 Appendix

References

Abbreviations 80

Exchange rates 81

About Datamonitor 82

Datamonitor consulting 82

Disclaimer 84

Browse complete Report on: Benchmarking the Pharmaceutical Market by Drug Delivery to 2014

Browse all Healthcare Market Research Reports

Browse all Life Science Analytics Market Research Reports

Browse all Newly Published Market Research Reports

Related Reports:

Drug Delivery Markets Implantable Injectable and Needle Free Delivery Systems

Drug Delivery Markets Oral Delivery

Innovations in Oral Solid Drug Delivery: Advances in nanotechnology, controlled formulations & peptide delivery

U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery 2010

Innovations in Injectables: Current and emerging technologies to improve drug delivery

About Us:

Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:

Ms. Sunita

7557 Rambler road,

Suite 727, Dallas, TX 75231

Tel: +1-888-989-8004

Website: http://www.reportsandreports.com/

Blog: http://reportsnreports.wordpress.com/

Blog: http://reportsandreports.blogspot.com/

Australia Pharmaceutical Market Overview - Reforms and continued price cuts will change the healthcare landscape now available at ReportsandReports

Dallas, TX: ReportsandReports announce it will carry Australia Pharmaceutical Market Overview – Reforms and continued price cuts will change the healthcare landscape Market Research Report in its Store.

Browse complete Pharmaceutical Market Report

Introduction

The prescription pharmaceutical market in Australia was valued at $9.1 billion in 2009. Key growth drivers include the growing use of chronic high-value innovative treatments driven by a rising elderly population and high public spending as a proportion of total healthcare expenditure.

Scope

* Overview of Australia’s socioeconomics and demographics, healthcare system, regulation, pricing and reimbursement and intellectual property position.

* Assesses the size of Australia’s pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies.

* Examines Australia’s generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion.

* Quantifies Australia’s R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis.

Highlights

Australia’s health expenditure totaled $81.8 billion, representing 9.1% of gross domestic product (GDP) in the financial year of 200708, which is the same percentage of GDP as the previous year. Australia’s health expenditure as a proportion of GDP has been comparable to that seen in Europe, with most of its spending coming from the government.

Lipitor (atorvastatin, Pfizer) generated significantly higher sales than any other brand on the Australian pharmaceutical market in 2009 ($550m). The second and third highest-selling brands, Crestor (rosuvastatin; AstraZeneca) and Nexium (esomeprazole; AstraZeneca), lag far behind Lipitor and did not even reach half of its sales.

Compared with Europe, where 17 biosimilars of five different molecules have been approved since 2006, Australia’s biosimilar market is small, particularly in terms of sales at $45,000. Somatropin is the only biologic that has biosimilar versions available, although the market is still very much dominated by the original branded product.

Reasons to Purchase

* Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access.

* Quantify the size and growth of the prescription pharmaceutical market in Australia, analyzing key therapy areas, brands and companies.

* Assess drivers and resistors of generic and biosimilars uptake in Australia and the level of erosion brands can expect to face post patent expiry.

Table Of Contents

ABOUT DATAMONITOR HEALTHCARE

About the Healthcare Strategic Analysis Team

Geographic-specific reports:

Global issue reports:

About the Healthcare Asia-Pacific Team

1. Australia – Executive Summary

Strategic scoping and focus

Key findings – healthcare drivers and resistors in Australia

Australia – Socio-demographic and economic analysis

Socio-demographic trends

Socio-economic trends

Australia – Healthcare system and drug regulatory analysis

Healthcare expenditure

Healthcare system overview

Regulatory issues

Pricing and reimbursement issues

Australia – Prescription pharmaceutical sales analysis

Pharmaceutical market size

Leading therapy areas

Leading prescription pharmaceutical brands

Leading pharmaceutical companies

Australia – Drug expiry analysis

Generics market

Brand erosion post patent expiry

Biosimilars market

Australia – Pharmaceutical industry infrastructure analysis

Pharmaceutical industry infrastructure overview

R&D infrastructure trends

Manufacturing infrastructure trends

Related reports

Upcoming related reports

Table of Contents

2. Australia – Socio-demographic and economic Analysis

Key findings

Socio-demographic trends

Socio-economic trends

Demographic trends in Australia

High population growth is a hot topic in Australia

Australia’s birth rate is expected to stabilize

Proportion of elderly individuals is set to rise

Australia’s life expectancy is one of the highest compared with other markets

Australia is a culturally and ethnically diverse country

Ischemic heart disease tops disease burden in Australia

Political climate in Australia

Federal elections are set for August 21, 2010

The 2010-11 Budget shows that the government’s priorities include reforms in health and hospitals

Memorandum of Understanding (MoU) is good for innovators, but not so good for generics companies

Fifth Community Pharmacy Agreement was received positively all around

Australia’s economy performs relatively well despite global downturn

Australia is doing comparatively well in the face of the global financial crisis

Unemployment rate experienced a small setback

Business environment in Australia

Corporate tax rate is high compared with other medium-sized OECD countries, but likely to be lowered

Unexpected price cuts led to uncertainty in Australia’s pharmaceutical business environment

Historically strong Australian biotechnology industry took a big hit from global downturn

3. Australia – Healthcare system and drug regulatory analysis

Key findings

Healthcare expenditure

Healthcare system overview

Regulatory issues

Pricing and reimbursement issues

Healthcare expenditure – Australia’s growth in pharmaceutical spending is under debate

Australia’s healthcare system

The structure of the Australian healthcare system is complex

Reforms aim to decrease complexity and inequalities by changing the funding and governance of health and hospitals

Government focuses on early intervention and the integration of care in the community

Medicare provides Australians with a range of free services

Medicare Australia funds and provides public healthcare services

Pharmaceutical Benefits Scheme (PBS) funds the use of prescription drugs

The Australian government promotes the uptake of private health insurance

GP Super Clinics will be established in order to improve access to primary care

Australia’s hospital system is split between a public and private market

Rural and Indigenous health are key focal points

National Medicines Policy aims to improve health outcomes through appropriate access to medicines

The Pharmaceutical Health and Rational Use of Medicines Committee and National Prescribing Service focus on quality use of medicines

Regulatory issues in Australia

Therapeutic Goods Administration (TGA) largely adopts EU standards

The Advisory Committee on Prescription Medicines (ACPM) has taken over from the Australian Drug Evaluation Committee (ADEC)

New organizational structure was put in place in mid-2010

New fees for the evaluation of prescription medicines

Therapeutic Goods Administration (TGA) reforms aim to reduce regulatory burden

Accelerated application entry and improved application coordination (streamlined submission process)

Increased transparency of prescription medicine regulatory process (the AusPAR project)

Improved access to prescription medicine information (the PI/CMI project)

The ‘biologicals framework’ refreshes regulations for biologicals

Intellectual property environment

Standard 20-year patent can be extended by up to 5 years

Data exclusivity is 5 years, during which ‘springboarding’ is allowed

Pricing reforms may encourage ‘evergreening’

Drug counterfeiting is less of a problem in Australia than in other developed markets

Drug importation is controlled by the government and patent holders

Drug reimbursement in Australia

Reimbursement is decided by the Pharmaceutical Benefits Advisory Committee (PBAC)

High level of evidence is needed for a drug to be added to reimbursement list

Transparency in PBAC decisions has improved

Probability of a positive PBAC outcome was 75% in 2009, but lower for major applications

Parallel applications to the TGA and PBAC will become possible from 2011

AUD10m ($7.9m) threshold for cabinet approval remains

Section 100 programs provide drugs under special arrangements

Drug pricing in Australia

Prices are negotiated by the Pharmaceutical Benefits Pricing Authority (PBPA)

Latest Pharmaceutical Benefits Scheme (PBS) reforms led to considerable drug price reductions

The price disclosure program singles out generics for further price cuts

Criticized ‘therapeutic groups’ have been put to a halt by the Memorandum of Understanding (MoU)

The PBPA uses different types of pricing models

Reference pricing method is mainly used for products in Formulary 1

Cost Plus method is mainly used for products in Formulary 2

Weighted Average Monthly Treatment Cost (WAMTC) is a key feature in therapeutic groups

Risk sharing agreements lack transparency

Special patient contributions apply in some cases

The Access to Medicines Working Group (AMWG) facilitates discussion between the government and pharmaceutical industry on PBS reforms

PBAC evaluates bDMARDs in cost-effectiveness review

Australian Government Productivity Commission highlights specific concerns about the regulation of medicines in Australia

Requirement for multiple ethics approvals

Timeliness and cost of manufacturing audits/GMP assessments

TGA transparency and communication

Concerns about PBS listing and pricing processes

Delays in achieving PBS listing due to overlapping processes

Concerns about marketing and advertising rules

Australia’s healthcare reforms

4. Australia – Prescription pharmaceutical sales analysis

Key findings

Pharmaceutical market size

Leading therapy areas

Leading prescription pharmaceutical brands

Leading pharmaceutical companies

Pharmaceutical market size in Australia

Leading therapy areas in Australia

Cardiovascular drugs hold the largest share of the Australian market value

Central nervous system products hold the second-largest share of the Australian market value

Musculoskeletal drugs exhibited the strongest growth in sales in 2005-09 and 2008-09

The hematology class experienced the most rapid decline in growth

Leading pharmaceutical brands in Australia

Lipitor achieved by far the highest sales in Australia in 2009, but generics are expected in 2012

Crestor experiences a huge uptake in sales but may face price cuts and uncertain patent protection

Nexium’s sales are going strong despite its price being linked to generic omeprazole

Leading companies in the Australian pharmaceutical market

Leading international companies active in Australia account for 63% of the pharmaceutical market

Leading Australian companies only make up 7% of the Australian pharmaceutical market

Sigma Pharmaceuticals

CSL

iNova Pharmaceuticals

5. Australia – Drug expiry analysis

Key findings

Generics market

Brand erosion post patent expiry

Biosimilars market

Australia generics market dynamics

Australia generics volume uptake

Australia generics value uptake

Drivers and resistors in the Australian generics market

Brand substitution is allowed if equivalence has been shown

Prevention of brand substitution by physicians is possible, but uncommon

Competing on price is difficult for generics manufacturers in Australia

High generics prices are targeted in continued price cuts

Pharmacists receive AUD1.50 for each script of a premium-free PBS drug they dispense

The Generic Medicines Industry Association (GMiA) unites key generics players

The National Prescribing Service (NPS) promotes generics education

Key generics players in Australia

Generic simvastatin is main single source of income for key generics players in Australia

Opportunities for the generics industry

Small molecule brand erosion in Australia

Overview of drugs analyzed

Mean level of brand erosion in Australia

Brand erosion in the Australian retail and hospital setting

Brand erosion by therapy area in Australia

Brand erosion by drug formulation in Australia

Biosimilars market dynamics in Australia

Drivers of biosimilar uptake – Australia bases its biosimilar approval pathway on that of the EU

Resistors of biosimilar uptake – limitations around reimbursement may cast a shadow over the commercial attractiveness of biosimilars in Australia

Somatropin is the only biosimilar available in Australia

Key players in the Australian biosimilars market

Monoclonal antibodies represent a major opportunity for the biosimilars industry

Over $400m in monoclonal antibody sales to go off-patent before 2015

However, branded monoclonal antibody uptake is currently hampered by reimbursement issues

International drivers and resistors to biosimilar monoclonal antibody uptake

Monoclonal antibody biosimilars in development internationally

6. Australia – Pharmaceutical industry infrastructure analysis

Key findings

Pharmaceutical industry infrastructure overview

R&D infrastructure trends

Manufacturing infrastructure trends

Overview of the pharmaceutical infrastructure in Australia

R&D and manufacturing strategies in Australia

Australia misses out as clinical trials are moved to Asia

Key company infrastructure in Australia

Pfizer

AstraZeneca

Sanofi-Aventis

GlaxoSmithKline

Novartis

Merck & Co.

Johnson & Johnson

Sigma Pharmaceuticals

Roche

Mylan

7. Bibliography

Australia – Executive Summary

Publications and online articles

Datamonitor reports and products

Australia – Socio-demographic and economic analysis

Publications and online articles

Australia – Healthcare system and drug regulatory analysis

Publications and online articles

Datamonitor reports and products

Australia – Prescription pharmaceutical sales analysis

Publications and online articles

Australia – Drug expiry analysis

Publications and online articles

Datamonitor reports and products

Australia – Pharmaceutical industry infrastructure analysis

Publications and online articles

APPENDIX

Exchange rate used in this report

Australia brand erosion – additional data

Australia brand erosion – methodology

Datamonitor prescription pharmaceutical definition and therapy area classification

About Datamonitor

About Datamonitor Healthcare

Datamonitor consulting

Disclaimer

Disclaimer

Browse complete Pharmaceutical Market Report

Browse all Healthcare Market Research Reports

Browse all Datamonitor Market Research Reports

Browse all Latest Report

Related Reports:

Australia Pharmaceuticals and Healthcare Report Q3 2010

Energy Market Landscape: Australia – Western Australia

Obama’s Healthcare Reform Bill and its Impact on the U.S. Healthcare Markets (Pharmaceuticals, Medical devices and Health insurance)

About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/